Edition:
India

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

350.80GBp
9:25pm IST
Change (% chg)

10.30 (+3.02%)
Prev Close
340.50
Open
339.10
Day's High
352.40
Day's Low
337.00
Volume
5,479,634
Avg. Vol
2,942,254
52-wk High
504.60
52-wk Low
238.00

Select another date:

Mon, Jul 16 2018

Indivior's shares soar 33 percent after U.S. court blocks sale of rival generic

Indivior Plc's shares jumped more than 33 percent on Monday after a U.S. court blocked a rival from selling a cheaper copycat of the British drugmaker's bestselling opioid addiction treatment.

UPDATE 1-Indivior's shares soar 33 pct after U.S. court blocks sale of rival generic

July 16 Indivior Plc's shares jumped more than 33 percent on Monday after a U.S. court blocked a rival from selling a cheaper copycat of the British drugmaker's bestselling opioid addiction treatment.

Indivior's shares jump 30 pct after U.S. court blocks sale of rival generic

July 16 Indivior Plc's shares soared as much as 30 percent on Monday after a U.S. court blocked India's Dr.Reddy's Laboratories from selling copycat versions of the British drugmaker's bestselling opioid addiction treatment in the United States.

BUZZ-India's Dr.Reddy's Laboratories plunges; Indivior wins preliminary injunction against co

** Dr.Reddy's Laboratories Ltd falls as much as 10.8 pct to a five-week low of 2,069.95 rupees

Indivior wins preliminary injunction against generic rival

A U.S. court has granted Indivior a preliminary injunction blocking India's Dr. Reddy's Laboratories from selling cut-price versions of the British drugmaker's best-selling opioid addiction treatment in the United States, Indivior said on Friday.

Indivior wins preliminary injunction against generic rival

A U.S. court has granted Indivior a preliminary injunction blocking India's Dr. Reddy's Laboratories from selling cut-price versions of the British drugmaker's best-selling opioid addiction treatment in the United States, Indivior said on Friday.

UPDATE 1-Indivior wins preliminary injunction against generic rival

July 13 A U.S. court has granted Indivior a preliminary injunction blocking India's Dr. Reddy's Laboratories from selling cut-price versions of the British drugmaker's best-selling opioid addiction treatment in the United States, Indivior said on Friday.

Britain's Indivior wins preliminary injuction against generic rival

July 13 A U.S. court has granted Indivior a preliminary injunction blocking India's Dr. Reddy's Laboratories from selling cut-price versions of the British drugmaker's best-selling opioid addiction treatment in the United States.

BUZZ-India's Dr.Reddy's rises on US drug hopes; UK rival Indivior cuts guidance

** Dr.Reddy's Laboratories Ltd rise as much as 3.8 pct to 2,387.65 rupees, its highest in 3 weeks

Indivior says 2018 profit to fall short after U.S. market hit

British drugmaker Indivior said on Wednesday its 2018 revenue and adjusted net income would come in below its previous forecast, hurt by the launch of generic versions of its bestselling opioid addiction treatment in the United States.

Select another date: